<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03717558</url>
  </required_header>
  <id_info>
    <org_study_id>W00035 PU 1 02</org_study_id>
    <nct_id>NCT03717558</nct_id>
  </id_info>
  <brief_title>Bioavailability Pilot Study of Versus W0035 Versus Stromectol</brief_title>
  <official_title>Comparative Bioavailability Pilot Study of 3 W0035 Test Oral Suspensions (Ivermectin 1mg/mL) Versus Stromectol® (Ivermectin, 3 mg Tablet) After Single Oral Administration in Healthy Volunteers. Single Centre, Open Label, Crossover, Randomized, 5-period, 20-sequence, Partial Replicate, Single Dose Design</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pierre Fabre Dermatology</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Pierre Fabre Dermatology</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Ivermectin is prescribed for the treatment of helminthic infections sensitive to ivermectin.
      However, it is currently only available as a tablet formulation. W0035 is a powder for oral
      suspension of ivermectin developed by PIERRE FABRE DERMATOLOGIE intended to be administered
      to children for the treatment of helminthic infections sensitive to ivermectin and mentioned
      in the Summary of Product Characteristics (SmPC) of Stromectol.

      PIERRE FABRE DERMATOLOGIE intends to carry out this pilot bioavailability study in order to
      define the most appropriate formulation to be used in the bioequivalence study.
    </textblock>
  </brief_summary>
  <overall_status>Withdrawn</overall_status>
  <why_stopped>
    Sponsor decision
  </why_stopped>
  <start_date type="Anticipated">April 30, 2018</start_date>
  <completion_date type="Anticipated">April 30, 2018</completion_date>
  <primary_completion_date type="Anticipated">April 30, 2018</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <intervention_model_description>Open label, crossover, randomized, 5-period, 20-sequence, partial replicate, single dose design</intervention_model_description>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Concentration of ivermectin</measure>
    <time_frame>5 periods of 3 days each</time_frame>
    <description>At each period: 17 blood samples: T0 (Pre-dose), T0 +15min, T0 +30min, T0 +1h, T0+1h30min, T0 +2h, T0 +2h30, T0 +3h, T0 +3h30, T0 +4h, T0 +4h30, T0 +5h, T0 +6h, T0 +12h, T0 +24h, T0 +48h and T0 +72h</description>
  </primary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">0</enrollment>
  <condition>Healthy Volunteers</condition>
  <arm_group>
    <arm_group_label>Stromectol R</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Stromectol R = ivermectin 3mg (tablet)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ivermectin T1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>T1= ivermectin low grade particle Size Distribution</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ivermectin T2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>T2= ivermectin medium grade particle Size Distribution</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ivermectin T3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>T= ivermectin high grade particle Size Distribution</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ivermectin T1</intervention_name>
    <description>Subjects will be randomly assigned to one of the 20 different sequences of on single dose of ivermectin (T1, T2, and T3) and two single doses of Stromectol</description>
    <arm_group_label>Stromectol R</arm_group_label>
    <arm_group_label>ivermectin T1</arm_group_label>
    <arm_group_label>ivermectin T2</arm_group_label>
    <arm_group_label>ivermectin T3</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ivermectin T2</intervention_name>
    <description>Subjects will be randomly assigned to one of the 20 different sequences of on single dose of ivermectin (T1, T2, and T3) and two single doses of Stromectol</description>
    <arm_group_label>Stromectol R</arm_group_label>
    <arm_group_label>ivermectin T1</arm_group_label>
    <arm_group_label>ivermectin T2</arm_group_label>
    <arm_group_label>ivermectin T3</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ivermectin T3</intervention_name>
    <description>Subjects will be randomly assigned to one of the 20 different sequences of on single dose of ivermectin (T1, T2, and T3) and two single doses of Stromectol</description>
    <arm_group_label>Stromectol R</arm_group_label>
    <arm_group_label>ivermectin T1</arm_group_label>
    <arm_group_label>ivermectin T2</arm_group_label>
    <arm_group_label>ivermectin T3</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  18.5 ≤ BMI ≤ 30.0 kg/m².

          -  Non-smoker subject with a breath carbon monoxide reading of ≤10 ppm at screening.

          -  Agree to use effective contraception method

        Exclusion Criteria: most specific out of 30.

          -  History of or current symptomatic orthostatic hypotension

          -  Hyper-eosinophilia or subject at risk of microfilaremic disease or clinical suspicion
             of intestinal helminth infection

          -  History of or current macroscopic or microscopic hematuria

          -  Positive serology for Hepatitis Bs antigen (HBs), Hepatitis C Virus (HCV) and HIV 1
             and 2 antibodies.

          -  Organic disorder likely to modify, absorption, distribution or elimination of the
             medication.
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>64 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Karim Keddad, MD</last_name>
    <role>Study Director</role>
    <affiliation>Institut de Recherche Pierre Fabre</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Quotient Clinical</name>
      <address>
        <city>Nottingham</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>October 2018</verification_date>
  <study_first_submitted>October 5, 2018</study_first_submitted>
  <study_first_submitted_qc>October 22, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">October 24, 2018</study_first_posted>
  <last_update_submitted>October 22, 2018</last_update_submitted>
  <last_update_submitted_qc>October 22, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">October 24, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ivermectin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

